The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends DOI Open Access
Ramadan Abdelmoez Farahat, Abdelaziz Abdelaal, Tungki Pratama Umar

et al.

Infezioni in Medicina, Journal Year: 2022, Volume and Issue: 30(4)

Published: Dec. 1, 2022

The SARS-CoV-2 Omicron variant (B.1.1.529) has been the most recent of concern (VOC) established by World Health Organization (WHO). Because its greater infectivity and immune evasion, this quickly became dominant type circulating worldwide. Our literature review thoroughly explains current state emergence, particularly comparing different omicron subvariants, including BA.2, BA.1, BA.3. Such elaboration would be based on structural variations, mutations, clinical manifestation, transmissibility, pathogenicity, vaccination effectiveness. notable difference between three subvariants is insufficiency deletion (Δ69-70) in spike protein, which results a lower detection rate (S) gene target known as failure (SGTF). Furthermore, BA.2 had stronger affinity to human Angiotensin-converting Enzyme (hACE2) receptor than other sub-lineages. Regarding number BA.1.1 (40), followed BA.3, BA.3 with 39, 34, 31 respectively. In addition, have transmissibility sub-lineages (BA.1 BA.1.1). These characteristics are primarily responsible for Omicron's vast geographical spread high contagiousness rates,

Language: Английский

Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster DOI Open Access
Chaitanya Kurhade, Jing Zou, Hongjie Xia

et al.

Nature Medicine, Journal Year: 2022, Volume and Issue: 29(2), P. 344 - 347

Published: Dec. 6, 2022

Language: Английский

Citations

384
SARS-CoV-2 viral load and shedding kinetics DOI Open Access
Olha Puhach, Benjamin Meyer, Isabella Eckerle

et al.

Nature Reviews Microbiology, Journal Year: 2022, Volume and Issue: unknown

Published: Dec. 2, 2022

Language: Английский

Citations

332
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2 DOI Creative Commons
Panke Qu, John P. Evans, Julia N. Faraone

et al.

Cell Host & Microbe, Journal Year: 2022, Volume and Issue: 31(1), P. 9 - 17.e3

Published: Nov. 22, 2022

Language: Английский

Citations

247
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England DOI Open Access
Freja Kirsebom, Nick Andrews, Julia Stowe

et al.

The Lancet Infectious Diseases, Journal Year: 2022, Volume and Issue: 22(7), P. 931 - 933

Published: May 24, 2022

Language: Английский

Citations

161
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3 DOI Open Access
Prerna Arora, Lu Zhang,

Cheila Rocha

et al.

The Lancet Infectious Diseases, Journal Year: 2022, Volume and Issue: 22(6), P. 766 - 767

Published: April 12, 2022

Language: Английский

Citations

94
First cases of SARS-CoV-2 BA.2.86 in Denmark, 2023 DOI Creative Commons
Morten Rasmussen, Frederik Trier Møller, Vithiagaran Gunalan

et al.

Eurosurveillance, Journal Year: 2023, Volume and Issue: 28(36)

Published: Sept. 7, 2023

We describe 10 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant BA.2.86 detected in Denmark, including molecular characteristics and results from wastewater surveillance that indicate the is circulating country at a low level. This new with many spike gene mutations was classified as under monitoring by World Health Organization on 17 August 2023. Further global COVID-19, other SARS-CoV-2 variants highly warranted.

Language: Английский

Citations

57
SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines DOI Creative Commons
Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: May 23, 2023

The highly transmissible Omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in late 2021. Initial waves were primarily made up sub-lineages BA.1 and/or BA.2, BA.4, and BA.5 subsequently became dominant mid-2022, several descendants these have since emerged. infections generally caused less disease on average than those by earlier variants concern healthy adult populations, at least, part, due to increased population immunity. Nevertheless, healthcare systems many countries, particularly with low immunity, been overwhelmed unprecedented surges prevalence during waves. Pediatric admissions also higher compared previous concern. All exhibit partial escape from wild-type (Wuhan-Hu 1) spike-based vaccine-elicited neutralizing antibodies, more enhanced immuno-evasive properties emerging over time. Evaluating vaccine effectiveness (VE) against has become challenging a complex background varying coverage, platforms, prior infection rates, hybrid Original messenger RNA booster doses substantially improved VE or BA.2 symptomatic disease. However, protection waned, reductions months after administration. While original CD8 + CD4 T-cell responses cross-recognize sub-lineages, thereby retaining outcomes, variant-adapted vaccines are required expand the breadth B-cell improve durability protection. Variant-adapted rolled out 2022 increase overall antigenically aligned immune mechanisms.

Language: Английский

Citations

51
Deep-learning-enabled protein–protein interaction analysis for prediction of SARS-CoV-2 infectivity and variant evolution DOI
Guangyu Wang, Xiaohong Liu, Kai Wang

et al.

Nature Medicine, Journal Year: 2023, Volume and Issue: 29(8), P. 2007 - 2018

Published: July 31, 2023

Language: Английский

Citations

44
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study DOI
Ida Rask Moustsen-Helms, Peter Bager, Tine Graakjær Larsen

et al.

The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(9), P. 964 - 973

Published: May 15, 2024

Language: Английский

Citations

35
Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models DOI Creative Commons
Lays Cordeiro Guimarães, Pedro Augusto Carvalho Costa, Sérgio Scalzo

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Jan. 18, 2024

Abstract A safe and effective vaccine with long-term protection against SARS-CoV-2 variants of concern (VOCs) is a global health priority. Here, we develop lipid nanoparticles (LNPs) to provide delivery plasmid DNA (pDNA) show VOCs in female small animal models. Using library LNPs encapsulating unique barcoded (b-DNA), screen for b-DNA after intramuscular administration. The top-performing are further tested their capacity pDNA uptake antigen-presenting cells vitro. lead LNP used encapsulate encoding the HexaPro version spike (LNP-HPS) immunogenicity vivo. LNP-HPS elicit robust protective effect Gamma (P.1), correlating reduced lethality, decreased viral load lungs lung damage. induce potent humoral T cell responses P.1, generate high levels neutralizing antibodies P.1 Omicron (B.1.1.529). Our findings indicate that efficacy elicited by comparable those achieved approved COVID-19 from Biontech/Pfizer Together, these suggest hold great promise as candidate VOCs.

Language: Английский

Citations

22